VBG provides occupational health and safety services, aiming to protect employees and organizations in their work environments. It provides services such as risk assessments, healthcare management, and insurance coverage related to workplace accidents and occupational diseases.

Fresenius SE & Co. KGaA, a health care company, provides products and services for dialysis, hospitals, and outpatient medical care. It operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment provides dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment engages in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune and oncology diseases; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operates 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 49 hospitals, 88 outpatient clinics, and approximately 300 risk prevention centers in Spain. This segment also provides services in the field of fertility treatments through 33 clinics and additional 39 sites across 10 countries on 3 continents. The Fresenius Vamed segment manages projects and offers services for hospitals and other health care facilities. This segment provides project development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Eduard Fresenius

Fresenius SE & Co. KGaA

Fresenius Kabi specializes in lifesaving medicines and technologies for critically and chronically ill patients and focuses on improving healthcare results. The company is involved in the fields of Pharma, Nutrition, MedTech, and Biopharma.

Fresenius Kabi

The uvex group is a leading company that develops, manufactures, and sells innovative products and services for the safety and protection of people at work, in sports, and during leisure time. The company is committed to sustainability, with a focus on economic, ecological, and social aspects, and has set targets to integrate sustainability considerations throughout its business processes.

Metric
Company Name	VBG	Fresenius SE & Co. KGaA	Fresenius Kabi	uvex group
Symbol		FRE
MSH ID	DE:VBG	COM:FRESENIUS	COM:FRESENIUS-KABI	COM:UVEX-GROUP
Market	PRIVATE	STOCKS	PRIVATE	PRIVATE
Sector	Commercial & Professional Services	Healthcare	Healthcare & Health Services	Consumer Goods
Industry	Health & Safety	Medical - Care Facilities	Pharmaceuticals	Safety and Protection Equipment
Country	DE	DE	DE
Stage		Post-IPO Equity
Employee Count	1.00K	190.86K	10.00K	1.00K
Website	vbg.de	fresenius.com	fresenius-kabi.com	uvex-group.com
LinkedIn		fresenius-se
Founders

Metric
Market Cap		17.24B
Enterprise Value
Monthly Web Traffic	3.56K	69.89K
Web Traffic Growth	12.47	-0.27
Valuation
Raised Capital

Metric
Revenue		23.55B
Revenue (LTM)
Revenue (NTM)
Gross Profit		5.34B
EBITDA		2.88B
Operating Income		1.21B
Net Income		-627.40M
EPS		-1.11
Diluted EPS		-1.11
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.23
Operating Profit Margin		0.06
EBITDA Margin		0.12
Net Profit Margin		-0.02
Return on Equity		-0.03
Return on Assets		-0.01
Return on Capital Employed		0.05

DE:VBG

VBG

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		52.33
P/B Ratio		0.72
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		0.87
EV Multiple		2.69

Metric
Days Sales Outstanding		374.30
Days Payables Outstanding		15.95
Days Inventory Outstanding		56.49
Operating Cycle		141.96
Cash Conversion Cycle		113.50
Asset Turnover		0.70

Metric
Operating Cash Flow		4.71B
Free Cash Flow		3.51B
Cash Flow to Debt		0.34
Operating Cash Flow/Sales		0.18
Free Cash Flow Yield		0.20

Metric
Cash & Equivalents		2.42B
Accounts Receivable		-278.84M
Inventory		2.66B
Goodwill		15.94B
Debt to Capitalization		0.45
Debt to Assets		0.20
Current Ratio		1.54
Quick Ratio		1.04

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		0.02
SG&A to Revenue		0.13